Ublituximab for Multiple Sclerosis

This trial explores a new treatment option for people with multiple sclerosis (MS) experiencing a "wearing off" of their current treatment, ocrelizumab. Researchers aim to determine if switching to ublituximab (a type of infusion therapy) can improve or delay the return of MS symptoms. Participants will either switch to ublituximab infusions or continue with ocrelizumab to compare outcomes. Individuals with relapsing forms of MS who have noticed worsening symptoms between ocrelizumab treatments might be suitable for this study.

As a Phase 4 trial, this research focuses on understanding how the already FDA-approved and effective treatment benefits more patients, offering a chance to contribute to broader knowledge while potentially improving personal care.

The trial does not specify if you need to stop taking your current medications, but you must be on ocrelizumab for at least one year to participate. It's best to discuss your current medications with the trial team.

Studies have shown that ublituximab is generally well tolerated by people with relapsing multiple sclerosis (MS). The most common side effects are mild and include manageable reactions during IV treatment. While receiving the treatment, some people might experience reactions, but they are usually not severe.

Research has also supported the safety of ublituximab over several years. For instance, in a group of patients who used the treatment for six years, the rate of MS relapses was very low. This suggests the treatment is not only effective but also safe for long-term use.

Ublituximab is unique because it offers a novel approach to treating multiple sclerosis (MS). Unlike standard treatments like Ocrelizumab that target CD20-positive B cells, Ublituximab is a glycoengineered antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC), making it potentially more effective in depleting B cells. Researchers are excited about Ublituximab because its engineered design might improve efficacy and safety profiles compared to existing therapies, possibly leading to better outcomes for patients with MS.

Research has shown that ublituximab, which participants in this trial may receive, effectively treats multiple sclerosis (MS). Studies indicate that patients using ublituximab experienced fewer MS flare-ups over time, as evidenced by a low and decreasing annualized relapse rate (ARR). Ublituximab also led to fewer brain lesions compared to teriflunomide, another MS drug. This treatment has proven effective and safe for relapsing MS over six years, suggesting it could benefit those whose current MS treatment is losing effectiveness. Participants in this trial will either switch from Ocrelizumab to Ublituximab or continue with Ocrelizumab.²³⁶⁷⁸